Formosa Laboratories, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019
August 12, 2019 at 06:38 pm EDT
Share
Formosa Laboratories, Inc. announced earnings results for the second quarter ended June 30, 2019. For the second quarter, the company announced sales was TWD 594.045 million compared to TWD 693.071 million a year ago. Operating loss was TWD 20.598 million compared to operating Income of TWD 13.940 million a year ago. Net loss was TWD 118.942 million compared to net income of TWD 27.264 million a year ago. Basic loss per share was TWD 1.2 compared to basic earnings per share of TWD 0.29 a year ago. For the half year, sales was TWD 1,248.367 million compared to TWD 1,305.681 million a year ago. Operating loss was TWD 117.797 million compared to operating Income of TWD 14.969 million a year ago. Net loss was TWD 86.801 million compared to net income of TWD 198.326 million a year ago. Basic loss per share was TWD 0.88 compared to basic earnings per share of TWD 2.13 a year ago. Diluted loss per share was TWD 0.88 compared to diluted earnings per share of TWD 2.12 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
FORMOSA LABORATORIES, INC. 
